Please login to the form below
FujiFilm
This page shows the latest FujiFilm news and features for those working in and with pharma, biotech and healthcare.
BMS and Century Therapeutics agree on deal potentially worth over $3bn
added. Forming part of the transaction is Century’s amendment to agreements made with FUJIFILM Cellular Dynamics for Japanese development and commercialisation rights for the products under the BMS collaboration.
Latest news
-
Novavax is close to finalising a COVID-19 vaccine supply deal with the EU
To support roll-out in the UK, Novavax partnered with FUJIFILM Diosynth Biotechnologies to manufacture certain components of the vaccine in the UK, including the protein antigen component.
-
GSK to assist in manufacturing up to 60 million doses of Novavax’s COVID-19 vaccine in the UK
Novavax also partnered with FUJIFILM Diosynth Biotechnologies to manufacture certain components of the vaccine in the UK, including the protein antigen component.
-
UK trial of Novavax COVID-19 vaccine demonstrates 89.3% efficacy
Novavax also partnered with FUJIFILM Diosynth Biotechnologies to manufacture certain components of the vaccine in the UK.
-
Novavax moves closer toward launch of US phase 3 COVID-19 vaccine trial
study. Novavax is planning to use vaccine material produced at a FUJIFILM Diosynth Biotechnologies plant in North Carolina to support the commercial scale-up required for phase 3 trials in the
-
Novavax starts first phase 3 COVID-19 vaccine trial in the UK
The UK government also signed a deal with Novavax in August, which led to the phase 3 clinical trial, and has also partnered with FUJIFILM Diosynth Biotechnologies to manufacture certain components
More from news
Approximately 2 fully matching, plus 13 partially matching documents found.
Latest Intelligence
-
Deal Watch March 2016
The sale of the diagnostic imaging business was believed to be hotly contested by Fujifilm and Konica Minolta, with Canon the successful bidder.
-
Pharma deals in July 2015
Still in Japan, a week later AZ agreed a joint venture with Fujifilm Kyowa Kirin Biologics for the development and commercialisation of a biosimilar version of bevacizumab (Avastin) in phase I ... Fujifilm Kyowa KirinBiologics will transfer the product
-
Pharma deals in March 2015
The high level of interest in cell therapies generally may have been one reason why Fujifilm acquired Cellular Dynamics for $307m at an eye watering share price premium of 108%. ... Fujifilm expects to achieve significant synergies. Checkpoint inhibitors
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
BIA elects six new board members
The remaining new appointments are Stephen Taylor of Fujifilm Diosynth Biotechnologies; Donna Hackett, director of life sciences consultancy firm KDH BioManagement; and Tim Watts, chief financial officer of Oxford BioMedica.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- World Health Organization releases new road map for breast cancer
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Making new year resolutions that can also benefit others
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- Omnichannel communications in Medical Affairs: closing the gap between aspiration and reality
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Meeting healthcare’s rising challenges
- Why female mentorship is so powerful in pharma
- AZ’s COVID-19 vaccine trial to continue after Brazilian volunteer death
PMHub
AMICULUM
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
